Discussions during the meeting focused on strengthening India’s preparedness against zoonotic diseases and climate-sensitive health challenges
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
Subscribe To Our Newsletter & Stay Updated
